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Results

Introduction

Flow cytometry gating strategy
Figure 1. A key to reading the flow cytometry data as
reference for the post. The plotted dots represent the cells
passed through the flow cytometry. They are stained for
identification of the markers MyoD and Noggin. Which
quadrant they lie on, demarcated by the green line,
represents which markers the cells expressed as detected
by flow cytometry.
Bottom left = no expression of MyoD and Nog (MyoD-/Nog-)
Top left = expression of MyoD only (MyoD+/Nog-)
Top Right = expression of both MyoD and Nog (MyoD+/Nog+)
Bottom Right = Expression of Nog only (MyoD-/Nog+)

(A) Trial 1
Non-treated cells (control) Doxorubicin treated cells (1μM)

Vincristine treated cells (10 nM)

Tumor heterogeneity and composition in response
to chemotherapy
A.

Drug resistant ERMS cells growing in SCID
mice restore original tumor composition

MyoD

Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in
childhood and adolescence. RMS rarely occurs in adults, but the outcome is
significantly worse. Most adult patients with advanced RMS die because their
cancer exhibits or develops resistance to available therapies. Chemotherapy
treatment for RMS includes Doxorubicin, a DNA intercalating agent and
topoisomerase II inhibitor, and Vincristine, a mitosis inhibitor.
Histologically, RMS is classified into two main subtypes, embryonal (ERMS) and
alveolar (ARMS). ARMS tumors typically harbor chromosomal translocations
resulting in the expression of PAX3- or PAX7-FOXO1 fusion proteins. ERMS tumors
exhibit a much wider range of genetic abnormalities. The fact that RMS of the
same subtype may have significant difference in clinical behavior has been well
recognized. Previously, we have shown that RMS cell lines propagated in vitro are
heterogeneous with respect to expression of Myoblast determination protein 1
(MyoD1) and Noggin (Nog). Importantly, MyoD+/Nog+ cells have shown higher
levels of chemoresistance to Vincristine and Doxorubicin than MyoD negative cells
in part to upregulation of anti-apoptotic genes Gli-1 and BcL2 (Dawson et al 2020).
Hypothesis:
We hypothesize that these Chemoresistant MyoD+/Nog+ cells are able to
reconstitute tumor heterogeneity when grown in vivo.

B.

Isotype controls

(B) Trial 2
Non-treated cells (control)

Material and Methods
Vincristine treated cells (10 nM)

Cell culture and treatment: Human ERMS cell lines RD (ATCC CCL-136) and A204
were cultured in DMEM media supplemented with 10% FCS, 1% antibiotic. Upon
reaching 70-80% confluency, cells were treated with either 10nM Vincristine, 1µM
Doxorubicin, or control medium (just culture medium) and incubated for 96 hours.
Dead (detached) cells were then removed by rinsing cells with PBS and live
adherent cells were harvested by treating cells with 0.25% trypsin/EDTA at 37oC.
In-vivo murine model: Following in vitro drug treatment for 4 days, cells
underwent a 3-day washout period. Live adherent cells were harvested, mixed
with Matrigel (1:1) and subcutaneously injected into severe combined immune
deficiency (SCID) mice (105 cells per injection). Tumors were harvested at 8 weeks
time point.
Sample preparation and staining: Tumor single cell suspensions were prepared
by mechanical disruption and Collagenase/DNase I digestion of tumor
tissues. Then tumor cells and ERMS cells growing in vitro were fixed and
permeabilized using Transcription factor buffer set (BD Biosciences) and stained
with panels of fluorochrome-labeled antibodies to the following markers: MyoD1,
Noggin and Bcl2.
In some experiments, cell proliferation assays were conducted using CellTrace
Violet cell proliferation kit according to the manufacturer’s protocol (Invitrogen).
Briefly, RMS cells were incubated in 5 uM of dye in PBS solution, washed, seeded
into 6-well plates at 0.4x106 cells per well and cultured for 4 days.
Flow Cytometry: Stained samples were run on 8-colors Stratedigm S1000EX
cytometer and analyzed using CellCapture software (Stratedigm). The same type of
cells stained with non-specific isotype controls were used to set gates for positive
vs negative subpopulations.

Isotype controls

Noggin
Cell divisions

Figure 2. Flow cytometry data demonstrates tumor heterogenicity as well as chemoresistance of
MyoD+Nog-, MyoD+Nog+ and MyoD-Nog+ subpopulations to the two primary chemotherapeutic
agents used to treat the disease, doxorubicin and vincristine. MyoD+Nog+ subpopulation exhibited
the highest resistance to chemotherapy than MyoD- cells to both drugs with 2.5-5.9-fold increase in
its fraction among live survived ERMS cells, in comparison to the composition of non-treated cells.
(panel A). Importantly, cytotoxic treatment with both drugs did not stop cell proliferation of drugresistant cells but just slowed -down their proliferation rate (panel B).

MyoD+/Nog+ cells show highest levels of
anti-apoptotic Bcl2 gene expression
Figure 3. MYOD1+ NOG+ cells express the highest
levels of antiapoptotic BCL2 protein among other
cells in the RD and A-204 cultures. Median
fluorescence intensity (MFI) of BCL2 protein in
MYOD1/NOG cell subpopulations of RD (left plot)
and A-204 (right plot) cell lines. Data represented
as ratio of BCL2 MFI of MYOD1+ NOG+ cells and
MYOD1- NOG+ cells to BCL2 MFI of MYOD1- NOGcells (change in folds), (mean +/- standard
deviation, N=9). ∗p<0.05, ∗∗p<0.01. Statistical
significance determined by ANOVA with Turkey’s
multiple comparison test).

Figure 4. Flow cytometry analysis demonstrates following 8 weeks of tumor growth in
SCID mice there is no significant difference between in cell composition of tumors
initiated by drug treated ERMS cells when compared to tumors initiated by injection of
non-treated ERMS cells. Two independent experiments were performed using the same
protocol. The first experiment (4-A) was done with both vincristine and doxorubicin
treated cells, however high level of doxorubicin autofluorescence limited its usage for
flow analysis, therefore the second experiment (4-B) was done only with vincristine. Each
plot represent individual tumor/mouse. Isotype control, account for stain
autofluorescence.

Conclusions
➢ MyoD+/Nog+ increase expression of antiapoptotic proteins and
are able to confer some degree of chemoresistance.
➢ These remaining MyoD+/Nog+ cells are also able to restore tumor
heterogeneity similar to that composition of the original tumor
composition seen in the non-treated tumors .
➢ MyoD+/Nog+ are able to restore their proliferation potential.
➢ This could be the basis for a mechanism partially explaining the
rebound tumors and metastasis that occur in adult RMS patients
after treatment.
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